Despite the significant reduction in CV mortality, CVOTs with SGLT2-Is demonstrated no benefit in reducing non-fatal atherosclerotic CV events, such as myocardial infarction and stroke. This evidence concerns the gene SLC5A2 and myocardial infarction.